NewEdge Advisors’s Invesco Pharmaceuticals ETF PJP Stock Holding History

NewEdge Advisors’s Portfolio PJP Stock Details PJP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.4K	Buy	240 +25	+12%	+$2.71K	﹤0.01%	3263
2026 Q1	$22.3K	Hold	215	–	–	﹤0.01%	3165
2025 Q4	$22.5K	Buy	+215	New	+$21.6K	﹤0.01%	3222
2023 Q3	–	Sell	-69	Closed	-$5.22K	–	3607
2023 Q2	$5.22K	Hold	69	–	–	﹤0.01%	2799
2023 Q1	$5.24K	Sell	69 -862	-93%	-$66.5K	﹤0.01%	2757
2022 Q4	$54.2K	Buy	+931	New	+$71.6K	﹤0.01%	1680
2017 Q3	–	Sell	-172	Closed	-$10.8K	–	915
2017 Q2	$10.8K	Buy	+172	New	+$10.3K	﹤0.01%	939

Other funds holding PJP

PAM

Peak Asset Management Louisville, Colorado $680M AUM 22.27% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

MML Investors Services Springfield, Massachusetts $49B AUM 25.55% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

JGCM

Joseph Group Capital Management Columbus, Ohio $476M AUM 21.21% 1-Year Est. Return

NewEdge Advisors's PJP Position: Q2 2026 in Review

NewEdge Advisors increased its Invesco Pharmaceuticals ETF (PJP) stake by 12% in Q2 2026, buying an estimated $2.71K and bringing the position to 240 shares worth $28.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3263.

NewEdge Advisors first reported a position in PJP in Q2 2017 and has held it in 7 quarters since. The position peaked at $54.2K in Q4 2022. 117 funds tracked by Wall St. Rank hold PJP as of Q2 2026.

NewEdge Advisors held 240 shares of Invesco Pharmaceuticals ETF worth $28.4K as of Q2 2026.
NewEdge Advisors bought 25 Invesco Pharmaceuticals ETF shares in Q2 2026, an estimated $2.71K.
Invesco Pharmaceuticals ETF made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3263 holding.
NewEdge Advisors first reported a position in Invesco Pharmaceuticals ETF in Q2 2017 and has held it in 7 quarters since.
NewEdge Advisors's Invesco Pharmaceuticals ETF position peaked at $54.2K in Q4 2022.
117 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.